Crewe Advisors’s Theravance Biopharma TBPH Stock Holding History

Crewe Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-131	Closed	-$1K	–	1256
2022 Q3	$1K	Hold	131	–	–	﹤0.01%	1205
2022 Q2	$1K	Buy	+131	New	+$1.21K	﹤0.01%	1106

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Crewe Advisors's TBPH Position: Q4 2022 in Review

Crewe Advisors sold out of Theravance Biopharma (TBPH) in Q4 2022, closing a stake of 131 shares — an estimated $1K sold.

Crewe Advisors first reported a position in TBPH in Q2 2022 and held it in 2 quarters. The position peaked at $1K in Q3 2022. 119 funds tracked by Wall St. Rank hold TBPH as of Q4 2022.

Crewe Advisors reported no remaining Theravance Biopharma position as of Q4 2022 after selling out during the quarter.
Crewe Advisors sold 131 Theravance Biopharma shares in Q4 2022, an estimated $1K.
Crewe Advisors first reported a position in Theravance Biopharma in Q2 2022 and held it in 2 quarters.
Crewe Advisors's Theravance Biopharma position peaked at $1K in Q3 2022.
119 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2022.

Based on Crewe Advisors's 13F filing for Q4 2022, filed 8 Feb 2023.